TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03455764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: MCS110 is a colony-stimulating factor-1 (CSF-1) inhibitor. It is a human monoclonal antibody which binds CSF-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: MCS110 is a colony-stimulating factor-1 (CSF-1) inhibitor. It is a human monoclonal antibody which binds CSF-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: MCS110 is a colony-stimulating factor-1 (CSF-1) inhibitor. It is a human monoclonal antibody which binds CSF-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib attack different proteins that promote the growth of cancerous cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib attack different proteins that promote the growth of cancerous cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib attack different proteins that promote the growth of cancerous cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib attack different proteins that promote the growth of cancerous cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib attack different proteins that promote the growth of cancerous cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib attack different proteins that promote the growth of cancerous cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib attack different proteins that promote the growth of cancerous cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib attack different proteins that promote the growth of cancerous cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib attack different proteins that promote the growth of cancerous cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib attack different proteins that promote the growth of cancerous cells
Study: NCT03157323

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low Glycemic Index Diet
Description: The nutritional intervention is theory-based and will provide nutritional education and counseling to children and their families. Nutritional counseling will be provided by the institutional designate and will focus on increasing patients' understanding of the benefits of a low GI diet, increase knowledge of low GI diet, overcoming barriers, and establishing expectations of the diet.
Study: NCT02227238

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two NRTIs
Description: Investigators will choose a dual NRTI background regimen for each subject . In consultation with the medical monitor, 3TC may be added as a third NRTI to a dual-NRTI background regimen in subjects with chronic HBV infection and evidence of HIV resistance to 3TC
Study: NCT00235560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Description: sirolimus
Study: NCT02395809

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral internal sphincterotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Study: NCT01465113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 28-day run-in phase during which subjects are treated with a proton pump inhibitor (omeprazole 20 mg po q day or an equivalent dose of another proton pump inhibitor).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 28-day run-in phase during which subjects are treated with a proton pump inhibitor (omeprazole 20 mg po q day or an equivalent dose of another proton pump inhibitor).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 28-day run-in phase during which subjects are treated with a proton pump inhibitor (omeprazole 20 mg po q day or an equivalent dose of another proton pump inhibitor).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: These patients (indefinite for dysplasia, LGD, or no dysplasia) will take vitamin D3 50,000 IU once a week for 12 weeks following the upper endoscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: These patients (indefinite for dysplasia, LGD, or no dysplasia) will take vitamin D3 50,000 IU once a week for 12 weeks following the upper endoscopy.
Study: NCT03778944

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol infusion
Description: Infusion of Mannitol 20% at a dose of 0.5 mg/kg to the renal graft donor after induction of anesthesia over 15 minutes.
Study: NCT01465113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Due to the risk of progression, subjects with Barrett's esophagus with high grade dysplasia will take vitamin D3 50,000 IU once a week for 2 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: upper endoscopy
Description: After the run-in phase subjects will undergo an upper endoscopy for Barrett's surveillance or Barrett's mapping as part of routine clinical care. At the time of endoscopy, in addition to large cup forceps biopsies obtained for surveillance or mapping as part of standard care, research biopsies will be obtained for the study. Following vitamin D3 supplementation, all subjects will undergo a repeat upper endoscopy for additional large cup forceps biopsies for measurement of post-treatment mucosal levels.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: upper endoscopy
Description: After the run-in phase subjects will undergo an upper endoscopy for Barrett's surveillance or Barrett's mapping as part of routine clinical care. At the time of endoscopy, in addition to large cup forceps biopsies obtained for surveillance or mapping as part of standard care, research biopsies will be obtained for the study. Following vitamin D3 supplementation, all subjects will undergo a repeat upper endoscopy for additional large cup forceps biopsies for measurement of post-treatment mucosal levels.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: upper endoscopy
Description: After the run-in phase subjects will undergo an upper endoscopy for Barrett's surveillance or Barrett's mapping as part of routine clinical care. At the time of endoscopy, in addition to large cup forceps biopsies obtained for surveillance or mapping as part of standard care, research biopsies will be obtained for the study. Following vitamin D3 supplementation, all subjects will undergo a repeat upper endoscopy for additional large cup forceps biopsies for measurement of post-treatment mucosal levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500mg for the first week, 1000mg during the second week, 1500mg during the third week, maximum dose of 2000mg in the fourth week
Study: NCT00990015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04308515
Description: Oral solution/suspension 0.1 mg up to potentially 350 mg QD at a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution/suspension to match active drug QD at a single dose.
Study: NCT02224846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered orally
Study: NCT05694819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide at a dose of 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide at a dose of 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin at a dose of 3.6 mg will be administered subcutaneously every 4 weeks.
Study: NCT02873715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based treatment
Description: Family based treatment as the invention to randomized participants. Family Based treatment utilizes behavior change techniques to target family-wide changes in diet and physical activity habits with the goal of promoting weight loss and subsequently healthy weight maintenance in all participants. Participants will have visits between 30 to 60 minutes as frequent as weekly and no longer than monthly over the two year study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care is a treatment that is normally provided to patients in pediatric offices by a pediatrician, physician assistant, or other primary care staff.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care is a treatment that is normally provided to patients in pediatric offices by a pediatrician, physician assistant, or other primary care staff.
Study: NCT03702257

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bronchoscopy.
Description: gDSAs are studied on cryopreserved biopsies obtained during bronchoscopy. The technique is the one described by Visentin J.
Study: NCT06529146

Intervention type: DRUG
Intervention: BHV-4157
Description: BHV-4157 (troriluzole) 200 mg QD
Study: NCT01412827

Intervention type: RADIATION
Group type: OTHER
Intervention: 1/2 dose of 99mTc OR 201Tl tracers
Description: Rest: Imaging will occur 30 to 60 minutes after injection of tracer.~Stress: All patients will undergo a symptom-limited Bruce protocol treadmill exercise test. At peak stress, the radiotracer will be injected intravenously, and exercise will continue for an additional 60 s. The patients who are unable to achieve the targeted heart rate or exercise will be stressed pharmacologically. Dipyridamole (0.142 mg/kg/min) will be infused intravenously for 5 minutes, and 99mTc radiotracer will be injected at 2 min after infusion completion (7 min into the study). Aminophylline (100-200 mg) will be given intravenously 2 min after injection of the radiotracer.
Study: NCT03103594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMSO
Description: DMSO will be instilled intravesically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMSO
Description: DMSO will be instilled intravesically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Botox will be instilled intravesically with DMSO.
Study: NCT01512628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentaspan, voluven, volulyte
Description: Different colloids are administered during operation for replacement of blood loss before the transfusion of blood.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentaspan, voluven, volulyte
Description: Different colloids are administered during operation for replacement of blood loss before the transfusion of blood.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentaspan, voluven, volulyte
Description: Different colloids are administered during operation for replacement of blood loss before the transfusion of blood.
Study: NCT02429583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombivax
Description: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombivax
Description: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment
Study: NCT02086474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronan
Description: Intra-articular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Extra-capsular injection
Study: NCT01857986

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AnapnoGuard 100 control unit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AnapnoGuard 100 control unit
Study: NCT02824510

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Algorithmic changes in insulin therapy.
Description: Based on SG evolution in first treadmill test, algorithms will evaluate the modifications in insulin therapy required to normalize SG during the second treadmill test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Algorithmic changes in insulin therapy.
Description: Based on SG evolution in first treadmill test, algorithms will evaluate the modifications in insulin therapy required to normalize SG during the second treadmill test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill exercises
Description: 25 min treadmill exercise at 60% of maximal heart rate estimated for age

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill exercises
Description: 25 min treadmill exercise at 60% of maximal heart rate estimated for age

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart, glargine and detemir
Study: NCT03778944

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine infusion
Description: Infusion of Dopamine at a dose of 4 microg/kg/min to the renal graft donor after induction of anesthesia till ligation of the renal artery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adequate hydration
Description: Infusion of Ringer Acetate at a rate of 15 ml/kg/hr to the renal graft donor after induction of anesthesia till ligation of the renal artery.
Study: NCT01687036

Intervention type: DEVICE
Group type: OTHER
Intervention: Cryoablation
Description: Cryoablation of Atrial Fibrillation Using a Novel Cryoablation System
Study: NCT01005043

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: heavy ion radiotherapy (C12)
Description: Desired target of Heavy ion radiotherapy is 60 to 66 Cobalt Gray Equivalent (GyE), whenever possible. It is applied through 1 - 3 isocenter treatment portals. Dose distributions are calculated and dose volume histograms (DVH) are generated. A α/β-ratio of 2 is used for biological plan optimization. Fractionation is planned to be equivalent to 6 x 3 GyE / week. Dosage to organs at risk is minimized. Treatment continues for 20 to 22 days or until one of the following criteria applies:~Other illness that prevents further administration of treatment, Patient or legal guardian decides to withdraw from the study, or changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator.
Study: NCT00179127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glargine
Description: 0.3u/kg of glargine, subcutaneously, once
Study: NCT02119104

Intervention type: DRUG
Intervention: Prevenar (13v)
Description: Prevenar (13v)
Study: NCT01418222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: Intravenous repeating dose
Study: NCT00179127

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 0.3u/kg of saline, subcutaneously, once
Study: NCT03961074

Intervention type: OTHER
Intervention: Iron deficiency anemia in Chinese pregnant women
Description: Iron deficiency anemia exists in Chinese pregnant women during pregnancy
Study: NCT04132245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Description: Families were randomized to a 14-week family based obesity prevention intervention or a 14-week general health intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obesity prevention intervention trial
Description: Families were randomized to a 14-week obesity prevention intervention or a 14-week general health intervention
Study: NCT03684252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based intervention
Description: Cognitive Behavioral Therapy (CBT) that uses acceptance and mindfulness strategies, together with commitment and behavior change strategies.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants' will receive treatment as usual.
Study: NCT02958384

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-LeY-CAR-transduced T cells
Description: The first 3 enrolled patients will receive autologous-derived LeY-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
Study: NCT00480974

Intervention type: OTHER
Intervention: Clinical follow up and laboratory analysis
Description: Clinical follow up and laboratory analysis
Study: NCT02138526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: pazopanib 800mg OD without food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pazopanib
Description: pazopanib 800mg OD without food

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: continental breakfast
Description: pazopanib 600mg OD with food
Study: NCT02997267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closure of the ileostomy
Description: Surgical closure of the protective ileostomy (reconnection of intestinal loops)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of the ileostomy
Description: Surgical closure of the protective ileostomy (reconnection of intestinal loops)
Study: NCT02746003

Intervention type: OTHER
Group type: OTHER
Intervention: Managed Aquifer Recharge water
Description: Rain water will be recharged through slow sand filter and recharge wells into the confined underground aquifer and the surrounding community will abstract the water for drinking and cooking purposes

Intervention type: OTHER
Group type: OTHER
Intervention: Managed Aquifer Recharge water
Description: Rain water will be recharged through slow sand filter and recharge wells into the confined underground aquifer and the surrounding community will abstract the water for drinking and cooking purposes
Study: NCT01227564

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001 3 μg/ QS-21 50 μg
Description: ACC-001 3 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001 10 μg/ QS-21 50 μg
Description: ACC-001 10 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
Study: NCT02775994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: interleukin beta (IL-1) antagonist
Study: NCT00691470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-5923
Description: Dose Adjusted based on INR.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coumadin (warfarin)
Description: Dose adjusted based on INR.
Study: NCT02768974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPRX-106
Description: Oral delivery, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPRX-106
Description: Oral delivery, once daily.
Study: NCT03541252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFL-assisted cisplatin+5-FU
Description: Patients will receive AFL-assisted cisplatin+5-FU as a treatment for their BCC. In brief, treatment areas consisting of tumors and a 5 mm margin will undergo CO2 laser exposure followed by 60 min topical application of a marketed and commercially available IV cisplatin solution (0.1%) After removal of cisplatin, a commercially distributed 5-FU cream (5%) will be applied to the treatment area at a dose of 0.125 ml per cm2 and left under occlusion. After skin evaluations on Day 1 and 5 after treatment, the same 5-FU dose will be applied, again left under occlusion. In total, 5-FU will remain on the skin for 7 days after AFL treatment whereafter it will be washed off. An additional repeat AFL-cisplatin+5-FU treatment on Day 30 will be offered if tumors persist, based on clinical evaluation and imaging on Day 30.
Study: NCT02143596

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: the infusion rate of normal saline is determinated by clinicians according to Bun/Cr ratio followed
Study: NCT00510848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autograft tendon
Description: Reconstruction with an autograft tendon (hamstrings)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allograft tendon
Description: Reconstruction with an allograft tendon (tibialis posterior)
Study: NCT02424435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Oral tablets of methylprednisolone 8 mg. Subjects will receive a monthly prescription bottle of 25 tablets (standard quantity) and will self-administer 21 tablets over a 28-day dosing cycle.
Study: NCT00827164

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutrition Counseling
Description: Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Patient will meet with an exercise specialist once per week for the first 6 weeks. Patients will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks.
Study: NCT01418222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Intravenous repeating dose
Study: NCT00672373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extract of Ginkgo Biloba (EGb-761 capsules)
Description: EGb-761 240mg/d, 1 capsule(80mg) tid,po,12 weeks; Each capsule contains 19.6mg flavonol glycosides and 4.8mg terpene lactones.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Wheat flour placebo capsule,1 capsule tid, po,12 weeks
Study: NCT00255814

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Study: NCT03909633

Intervention type: BEHAVIORAL
Intervention: a series of tests
Description: all patients in every group will do a series of tests,including DSST、DST、MoCA、WCST、HADS

Intervention type: BEHAVIORAL
Intervention: a series of tests
Description: all patients in every group will do a series of tests,including DSST、DST、MoCA、WCST、HADS